☰

ExploRNATherapeutics

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of ExploRNATherapeutics's published strategy and is not endorsed by, or produced in cooperation with, ExploRNATherapeutics. Company website

Strategic priorities

ExploRNATherapeutics operates across 4 stated priorities, with the most concrete near-term plan anchored on revolutionize mrna manufacturing.

Develop superior cap analogs (AvantCap series) that surpass current industry standards like TriLink's CleanCap, achieving higher protein expression with lower mRNA doses.

Reduce vaccine and therapeutic production costs through optimized chemistry, as mandated by the Gates Foundation partnership for global health accessibility.

Build strategic alliances with RNA polymerase specialists (Primrose Bio) and LNP delivery experts (Acuitas) to create comprehensive mRNA production solutions.

Challenges we see

  • Operations Manufacturing

    Process Scale-Up Bottleneck

    ExploRNA must transition from PhD-chemist-optimized benchtop synthesis (milligrams) to industrial-scale GMP production (kilograms) at CDMO partner facilities.

    The multi-step organic synthesis of AvantCap analogs involves sensitive reagents and precise parameters that do not translate 1:1 from glass columns to steel reactors, risking batch failures and yield loss during tech transfer.

  • Digital Integration

    Fragmented Data Architecture

    Chemistry teams (using ChemDraw/ELNs) and Biology teams (using GraphPad Prism, flow cytometry software) operate in separate data silos, preventing AI-driven structure-activity correlation.

    Manual Excel aggregation of structure-performance data hampers predictive modeling for lead optimization, slowing R&D iteration cycles against competitors like TriLink.

  • Operations Operations

    Manual QC Workflow Burden

    HPLC and Mass Spectrometry data is manually transcribed into spreadsheets to generate Certificates of Analysis (CoA), a process that scales linearly with sales volume.

    As commercial orders grow with partnerships like Primrose Bio, manual QC processing drives release delays and transcription error risks that could damage customer trust.

  • Digital Regulatory

    Partnership Data Security Risk

    Strategic collaborations with Primrose Bio (US) and Acuitas (Canada) require constant exchange of proprietary performance data across continents.

    Email-based PDF/Excel sharing creates version control chaos and IP exposure risks, threatening the competitive advantage of ExploRNA's core molecular innovations.

  • Compliance Regulatory

    GMP Compliance Gap

    ExploRNA achieved ISO 9001:2015 certification in April 2025, but pharma partners require GMP-compliant reagents for clinical trials—an exponentially higher documentation burden.

    Paper-based logbooks and manual instrument logs cannot meet ALCOA+ data integrity requirements, risking audit findings that could halt critical partnerships.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Tech Transfer Process Reproducibility

    Synthesis protocols optimized in Warsaw labs must be digitally replicated at CDMO partner sites without fidelity loss. Any discrepancy in parameters causes batch failures and regulatory delays.

    Implement Digital Process Twins that model reaction kinetics and thermodynamics, allowing simulation of scale-up parameters before physical tech transfer, reducing CDMO batch failure risk by 50%+.

  2. Cross-Atlantic R&D Data Synchronization

    Primrose Bio collaboration requires real-time sharing of experimental data (yields, purity profiles, transcription rates) between Warsaw and San Diego, but current methods involve email and unsecured file transfers.

    Deploy a secure, cloud-native Collaboration Data Room with Role-Based Access Control, enabling partners to view performance metrics without accessing underlying molecular IP.

  3. QC Data Pipeline Automation

    HPLC/MS output is manually transcribed into spreadsheets to generate CoAs, creating a bottleneck that scales linearly with order volume and introduces transcription errors.

    Build middleware that parses raw instrument data files, calculates purity percentages automatically, and generates CoAs without human intervention—reducing "Release Time" by 70%+.

  4. Research Knowledge Graph Unification

    Chemistry data (molecular structures) and Biology data (expression results) exist in incompatible software stacks, preventing AI/ML from learning optimal structure-activity relationships.

    Deploy a Data Lakehouse architecture that ingests both structured chemistry data and unstructured biological results into a unified graph, enabling queries like "Show all cap analogs with benzyl modification achieving >50% translation efficiency."

  5. GMP Audit Readiness Infrastructure

    ISO 9001 certification is insufficient for pharma partners who need GMP-compliant reagents for clinical trials. Current paper-based workflows cannot meet ALCOA+ data integrity requirements at scale.

    Implement an electronic Quality Management System (eQMS) with Electronic Batch Records (EBR) that enforces compliance (preventing process steps if equipment is out of calibration) and creates immutable audit trails.

What we'd propose

  • Digital CDMO

    Digital Process Twin for mRNA Synthesis

    A computational model of the cap analog synthesis reaction that simulates the impact of scale-up parameters (vessel size, heat transfer, mixing dynamics) before physical tech transfer to CDMO partners.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Secure Partner Collaboration Platform

    A cloud-native, RBAC-protected data exchange environment enabling real-time collaboration with Primrose Bio and Acuitas while protecting core molecular IP.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Automated QC Data Pipeline & CoA Generation

    Middleware connecting HPLC and Mass Spectrometry instruments directly to a LIMS layer, automating purity calculations and Certificate of Analysis generation without human transcription.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Unified Research Knowledge Graph

    A Data Lakehouse architecture integrating chemistry (structure) and biology (function) data into a queryable graph enabling AI-driven lead optimization.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    eQMS and GMP Compliance Automation

    Electronic Quality Management System with Electronic Batch Records that enforces ALCOA+ data integrity and creates immutable audit trails for FDA/EMA readiness.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what ExploRNATherapeutics's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 30 → 80
Chemistry and biology data exist in separate silos (ChemDraw vs GraphPad), requiring manual Excel aggregation for cross-domain analysis
Process Digitalization 35 → 85
Synthesis protocols are documented in paper SOPs; HPLC/MS data manually transcribed; no digital process twins for scale-up simulation
Quality Systems 45 → 90
ISO 9001 achieved but far from GMP; paper logbooks cannot meet ALCOA+ requirements for pharma partnerships
Cloud & Collaboration 25 → 75
Partner data exchange via email/PDF; no secure cloud infrastructure for real-time cross-Atlantic collaboration with Primrose Bio/Acuitas
Analytics & AI 20 → 70
No ML models for structure-activity prediction; manual correlation between chemical modifications and biological performance
Cybersecurity 40 → 80
Academic infrastructure (University of Warsaw) may not meet Big Pharma security standards; need commercial zone network segregation

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with ExploRNATherapeutics, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].